• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,093
79
60
57
47

COUNTRY

55
17
8
6
5

CATEGORIES

  • 82
  • 121
  • 66
  • 66
  • 36
  • 37
  • 12
  • 11
  • 12
  • 18

PRICE

545
810
1,719
2,600

PUBLISHED

214
314
747
2,600

PRODUCT TYPE

2,454
71
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

GSK1572932A ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

GSK1572932A ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Avastin (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Avastin (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players”. The...

June 2013
FROM

LDK378 (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

LDK378 (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013 Summary 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013', provides an overview...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Dacomitinib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Dacomitinib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Iressa (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Iressa (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

Custirsen (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Custirsen (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Onartuzumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Onartuzumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Nivolumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Nivolumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Esophageal Cancer - Pipeline Review, H1 2013

'Esophageal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Esophageal Cancer, complete...

June 2013
FROM

Carcinomas - Pipeline Review, H1 2013

Carcinomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

June 2013
FROM

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2013

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H1 2013 Summary 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2013', provides an overview of the indication's...

June 2013
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)